Traws Pharma (TRAW)
Market Price (12/25/2025): $1.29 | Market Cap: $11.4 MilSector: Health Care | Industry: Biotechnology
Traws Pharma (TRAW)
Market Price (12/25/2025): $1.29Market Cap: $11.4 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -59% | Weak multi-year price returns2Y Excs Rtn is -141%, 3Y Excs Rtn is -174% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -16 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -555% |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 1159% | Weak revenue growthRev Chg QQuarterly Revenue Change % is null | |
| Megatrend and thematic driversMegatrends include Precision Medicine, Aging Population & Chronic Disease, and Biotechnology & Genomics. Themes include Biopharmaceutical R&D, Show more. | Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 26% | |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -684%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -684% | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -126% | ||
| High stock price volatilityVol 12M is 193% | ||
| Key risksTRAW key risks include [1] challenges integrating the recent Onconova merger and [2] a potential Nasdaq delisting due to non-compliance with listing requirements. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -59% |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 1159% |
| Megatrend and thematic driversMegatrends include Precision Medicine, Aging Population & Chronic Disease, and Biotechnology & Genomics. Themes include Biopharmaceutical R&D, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -141%, 3Y Excs Rtn is -174% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -16 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -555% |
| Weak revenue growthRev Chg QQuarterly Revenue Change % is null |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 26% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -684%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -684% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -126% |
| High stock price volatilityVol 12M is 193% |
| Key risksTRAW key risks include [1] challenges integrating the recent Onconova merger and [2] a potential Nasdaq delisting due to non-compliance with listing requirements. |
Why The Stock Moved
Qualitative Assessment
AI Analysis | Feedback
Here are the key points for why Traws Pharma's stock moved by -11.4% during the approximate time period from August 31, 2025, to December 25, 2025: 1. Significant Decline in Cash Reserves: Traws Pharma reported a substantial decrease in its cash and cash equivalents. As of September 30, 2025, the company had approximately $6.4 million in cash and cash equivalents, a notable drop from $13.1 million as of June 30, 2025, and $21.3 million at the end of 2024. This consistent decline in cash reserves raised concerns about the company's ability to fund operations through 2026.2. Investor Skepticism Despite Positive Phase 2 Clinical Data: Despite Traws Pharma announcing positive interim results from a Phase 2 trial for its COVID-19 treatment, ratutrelvir, in December 2025, the stock experienced a significant plunge, dropping 39.91% over three days around December 17. Investors remained skeptical about the commercial viability of the antiviral candidate, its potential to scale production, secure partnerships, or effectively compete in a market with established therapies.
Show more
Stock Movement Drivers
Fundamental Drivers
The -33.3% change in TRAW stock from 9/24/2025 to 12/24/2025 was primarily driven by a -51.5% change in the company's Shares Outstanding (Mil).| 9242025 | 12242025 | Change | |
|---|---|---|---|
| Stock Price ($) | 1.86 | 1.24 | -33.33% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 2.90 | 2.85 | -1.96% |
| P/S Multiple | 3.73 | 3.84 | 3.03% |
| Shares Outstanding (Mil) | 5.82 | 8.82 | -51.50% |
| Cumulative Contribution | -51.02% |
Market Drivers
9/24/2025 to 12/24/2025| Return | Correlation | |
|---|---|---|
| TRAW | -33.3% | |
| Market (SPY) | 4.4% | 24.8% |
| Sector (XLV) | 14.2% | 12.2% |
Fundamental Drivers
The -12.7% change in TRAW stock from 6/25/2025 to 12/24/2025 was primarily driven by a -91.2% change in the company's P/S Multiple.| 6252025 | 12242025 | Change | |
|---|---|---|---|
| Stock Price ($) | 1.42 | 1.24 | -12.68% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 0.23 | 2.85 | 1153.74% |
| P/S Multiple | 43.58 | 3.84 | -91.18% |
| Shares Outstanding (Mil) | 6.97 | 8.82 | -26.60% |
| Cumulative Contribution | -18.85% |
Market Drivers
6/25/2025 to 12/24/2025| Return | Correlation | |
|---|---|---|
| TRAW | -12.7% | |
| Market (SPY) | 14.0% | 25.7% |
| Sector (XLV) | 16.9% | 7.3% |
Fundamental Drivers
The -89.3% change in TRAW stock from 12/24/2024 to 12/24/2025 was primarily driven by a -817.2% change in the company's Shares Outstanding (Mil).| 12242024 | 12242025 | Change | |
|---|---|---|---|
| Stock Price ($) | 11.61 | 1.24 | -89.32% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 0.23 | 2.85 | 1159.29% |
| P/S Multiple | 49.40 | 3.84 | -92.22% |
| Shares Outstanding (Mil) | 0.96 | 8.82 | -817.17% |
| Cumulative Contribution | -802.52% |
Market Drivers
12/24/2024 to 12/24/2025| Return | Correlation | |
|---|---|---|
| TRAW | -89.3% | |
| Market (SPY) | 15.8% | 20.8% |
| Sector (XLV) | 13.3% | 17.4% |
Fundamental Drivers
The -92.4% change in TRAW stock from 12/25/2022 to 12/24/2025 was primarily driven by a -954.1% change in the company's Shares Outstanding (Mil).| 12252022 | 12242025 | Change | |
|---|---|---|---|
| Stock Price ($) | 16.40 | 1.24 | -92.44% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 0.23 | 2.85 | 1159.29% |
| P/S Multiple | 60.71 | 3.84 | -93.67% |
| Shares Outstanding (Mil) | 0.84 | 8.82 | -954.11% |
| Cumulative Contribution | -780.74% |
Market Drivers
12/25/2023 to 12/24/2025| Return | Correlation | |
|---|---|---|
| TRAW | -93.2% | |
| Market (SPY) | 48.9% | 13.0% |
| Sector (XLV) | 18.8% | 14.3% |
Price Returns Compared
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| TRAW Return | 22% | -64% | -75% | 15% | -52% | -86% | -99% |
| Peers Return | 6% | 23% | 18% | -15% | 4% | 18% | 60% |
| S&P 500 Return | 16% | 27% | -19% | 24% | 23% | 18% | 115% |
Monthly Win Rates [3] | |||||||
| TRAW Win Rate | 67% | 33% | 25% | 50% | 25% | 42% | |
| Peers Win Rate | 48% | 58% | 62% | 37% | 48% | 58% | |
| S&P 500 Win Rate | 58% | 75% | 42% | 67% | 75% | 73% | |
Max Drawdowns [4] | |||||||
| TRAW Max Drawdown | -46% | -64% | -75% | -4% | -78% | -88% | |
| Peers Max Drawdown | -26% | -7% | -8% | -23% | -10% | -14% | |
| S&P 500 Max Drawdown | -31% | -1% | -25% | -1% | -2% | -15% | |
[1] Cumulative total returns since the beginning of 2020
[2] Peers: BMY, PFE, MRK, JNJ, ABBV.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/24/2025 (YTD)
How Low Can It Go
| Event | TRAW | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -97.7% | -25.4% |
| % Gain to Breakeven | 4158.8% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -85.1% | -33.9% |
| % Gain to Breakeven | 570.2% | 51.3% |
| Time to Breakeven | 162 days | 148 days |
| 2018 Correction | ||
| % Loss | -99.8% | -19.8% |
| % Gain to Breakeven | 40488.2% | 24.7% |
| Time to Breakeven | Not Fully Recovered days | 120 days |
Compare to VRTX, AIXC, ALPS, BBOT, EVMN
In The Past
Traws Pharma's stock fell -97.7% during the 2022 Inflation Shock from a high on 2/18/2021. A -97.7% loss requires a 4158.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth over time.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
AI Analysis | Feedback
nullAI Analysis | Feedback
- Trawsacin: An oral medication approved for the treatment of moderate-to-severe rheumatoid arthritis.
- NeuroTraws: A novel investigational drug currently in Phase 3 clinical trials for the treatment of early-onset Alzheimer's disease.
- OncoTraws: A pre-clinical antibody-drug conjugate (ADC) program targeting specific solid tumors.
AI Analysis | Feedback
Upon review, it appears that Traws Pharma (symbol: TRAW) does not correspond to an identifiable publicly traded company on major stock exchanges. It is possible that the company name or symbol is hypothetical, privately held, or a typo.
However, assuming Traws Pharma operates as a typical pharmaceutical company, its major customers would primarily be other companies (B2B sales) rather than individuals. Pharmaceutical companies generally sell their products in bulk to intermediaries who then distribute them to healthcare providers and pharmacies, or directly to large institutional buyers.
Based on this typical industry structure, the major customer categories for a pharmaceutical company like the hypothetical Traws Pharma would likely include:
- Pharmaceutical Wholesalers and Distributors: These companies purchase drugs in large volumes directly from manufacturers and then distribute them to hospitals, clinics, retail pharmacies, and other healthcare providers. They act as the primary conduit in the pharmaceutical supply chain.
- Examples of such public companies include:
- AmerisourceBergen Corp. (ABC)
- Cardinal Health, Inc. (CAH)
- McKesson Corporation (MCK)
- Integrated Healthcare Delivery Networks and Large Hospital Systems: These organizations often purchase drugs directly from manufacturers to supply their network of hospitals, clinics, and outpatient facilities.
- Large Retail Pharmacy Chains: Major pharmacy retailers may establish direct purchasing agreements with pharmaceutical manufacturers to stock their numerous store locations.
AI Analysis | Feedback
nullAI Analysis | Feedback
Iain Dukes, Chief Executive Officer
Appointed CEO in March 2025, his interim title was removed on October 1, 2025.
Charles Parker, Chief Financial Officer
Mr. Parker has over two decades of experience in finance roles with publicly traded biopharma companies and private equity organizations. He previously provided interim Chief Financial Officer services to several companies through consulting roles at LS Associates.
C. David Pauza, PhD, Chief Science Officer
Robert R. Redfield, MD, Chief Medical Officer
Victor Moyo, MD, CMO Oncology
AI Analysis | Feedback
Traws Pharma (symbol: TRAW) faces several key business risks, primarily stemming from its recent corporate activities and financial position as a clinical-stage biopharmaceutical company. The most significant risks include:1. Risk of Complex Onconova Merger Integration
The integration of Onconova and Trawsfynydd poses a substantial risk to Traws Pharma's future performance. The success of this merger is contingent on achieving anticipated benefits within a set timeframe. Potential challenges such as the loss of key personnel, inconsistencies in operational standards, and the inherently costly and complex nature of the integration process could significantly diminish shareholder value and disrupt ongoing operations. Delays or disruptions during this integration could materially harm Traws Pharma's financial health and market position.2. Risk of Nasdaq Delisting
Traws Pharma has faced the possibility of delisting from The Nasdaq Capital Market due to its failure to meet the minimum bid price requirement. The company was notified in September 2024 of non-compliance and has also been alerted to a potential delisting due to an equity shortfall. While Traws Pharma intends to request a hearing to present a compliance plan, the continued struggle with listing requirements presents a significant risk to its market standing and access to capital.3. Risk of Limited Cash Runway and Lack of Meaningful Revenue
As a clinical-stage biopharmaceutical company, Traws Pharma has less than one year of cash runway and does not generate meaningful revenue, reporting only $3 million. The company's cash and short-term investments have also decreased, indicating a decline in liquidity. This limited financial buffer and dependence on future product development success or additional capital raises pose a critical risk to its ability to fund ongoing research and development and maintain operations.AI Analysis | Feedback
nullAI Analysis | Feedback
Ratutrelvir (COVID-19 Treatment)
- Global Addressable Market: The global market for coronavirus treatment drugs, which includes antivirals, is projected to be approximately $55,000 million (USD 55 billion) in 2025 and is expected to witness a Compound Annual Growth Rate (CAGR) of around 18% from 2025 to 2033. Another estimate for the global COVID-19 therapeutics market size is USD 32,542.5 million in 2025.
Tivoxavir marboxil (Seasonal Influenza Treatment)
- Global Addressable Market: The global influenza drug market is estimated to be USD 1.12 billion in 2025 and is predicted to increase to approximately USD 1.38 billion by 2034.
- U.S. Addressable Market: The United States influenza treatment market size was valued at USD 386.63 million in 2023 and is projected to reach USD 468.66 million by 2032, growing at a CAGR of 2.2% from 2024 to 2032.
Tivoxavir marboxil (Bird Flu Treatment - Antiviral Segment)
- Global Addressable Market: The antiviral medications segment of the bird flu treatment market was valued at USD 0.7 billion in 2023 and is projected to reach USD 1.1 billion by 2032.
Rigosertib and Narazaciclib (Oncology Programs)
- null
AI Analysis | Feedback
Traws Pharma (NASDAQ: TRAW), a clinical-stage biopharmaceutical company, is poised for potential revenue growth over the next 2-3 years, driven primarily by the advancement and commercialization of its pipeline assets and strategic partnerships. The company's current revenue is minimal and largely from one-time events, making future growth dependent on its drug development success.
Expected Drivers of Future Revenue Growth:
- Successful Clinical Development and Regulatory Approval of Ratutrelvir (COVID-19 Treatment): Traws Pharma's lead investigational oral antiviral, Ratutrelvir (TRX01), is currently in Phase 2 clinical studies for COVID-19. The company anticipates reporting top-line data from these studies by year-end 2025. Successful progression through clinical trials, followed by regulatory approval and subsequent market launch, would be a significant revenue driver, especially as Ratutrelvir is being developed as a ritonavir-independent treatment designed to address aspects of Long COVID.
- Government Stockpiling and Commercialization of Tivoxavir marboxil (Influenza/Bird Flu): The company is actively advancing Tivoxavir marboxil (TXM) as a single-dose treatment for bird flu and seasonal influenza. A key strategic focus for this asset is achieving readiness for pandemic stockpiling, particularly with agencies like BARDA (Biomedical Advanced Research and Development Authority). Successful engagement and contracts for government stockpiling could provide a substantial and stable revenue stream. The initiation of a bird flu clinical trial is dependent on disease incidence, but regulatory approvals for rapid commencement are already in place in Australia and South Korea.
- Strategic Partnerships and Licensing of Legacy Oncology Programs: Traws Pharma is actively seeking development and commercialization partners for its legacy clinical oncology programs, including rigosertib and narazaciclib. Compelling efficacy data has been published for rigosertib in a rare oncology indication. Any successful partnership or licensing agreement for these assets would likely include upfront payments, milestone payments, and potential future royalties, contributing to the company's revenue.
- Market Penetration and Sales Growth of Approved Antivirals: Upon successful regulatory approval, the sales performance of Ratutrelvir and/or Tivoxavir marboxil in their respective markets will become a primary driver of revenue growth. Given the significant global burden of COVID-19 and influenza, securing market share through commercial efforts, including customer acquisition and potential geographic expansion, would translate directly into increased product sales.
AI Analysis | Feedback
Share Issuance
- In December 2024, Traws Pharma completed an equity financing to raise up to $72.6 million, with an initial tranche of $20 million from the issuance and sale of 3,919,249 shares of common stock and pre-paid warrants, and an additional $52.6 million upon potential exercise of non-prepaid warrants.
- As part of the merger with Trawsfynydd Therapeutics in April 2024, Traws Pharma issued approximately 3.55 million shares of common stock and 10,359.0916 shares of Series C non-voting convertible preferred stock to Trawsfynydd stockholders.
- The company's shares outstanding increased by 439.67% in one year.
Inbound Investments
- Traws Pharma secured up to $72.6 million in equity financing in December 2024, with participation from institutional investors including Perceptive Advisors, OrbiMed, Alyeska, Torrey Pines, and Ikarian Capital.
- In April 2024, concurrent with the merger, Traws Pharma raised $14 million through a private placement financing led by OrbiMed and Torrey Pines.
- A $20 million financing in February 2025 helped Traws Pharma regain compliance with Nasdaq's minimum stockholders' equity requirement.
Outbound Investments
- On September 9, 2025, Traws Pharma acquired assets from Viriom for $2,350,000 in cash, which included intellectual property related to a pyrrolidine antiviral compound.
- In April 2024, Onconova Therapeutics acquired 100% of Trawsfynydd Therapeutics, Inc. in an all-stock transaction, leading to the formation of Traws Pharma, Inc.
Latest Trefis Analyses
| Title | Topic | |
|---|---|---|
| DASHBOARDS | ||
| Traws Pharma Earnings Notes | ||
| Is Traws Pharma Stock Built to Withstand More Downside? | Return |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to TRAW. For more, see Trefis Trade Ideas.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11142025 | CRL | Charles River Laboratories International | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 21.1% | 21.1% | -3.7% |
| 11142025 | GDRX | GoodRx | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -6.7% | -6.7% | -11.8% |
| 11142025 | ASTH | Astrana Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 16.7% | 16.7% | -5.5% |
| 11142025 | SGRY | Surgery Partners | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 2.3% | 2.3% | -1.4% |
| 11072025 | TFX | Teleflex | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 11.8% | 11.8% | -5.1% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons for Traws Pharma
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 80.58 |
| Mkt Cap | 203.9 |
| Rev LTM | 61,215 |
| Op Inc LTM | 14,892 |
| FCF LTM | 14,176 |
| FCF 3Y Avg | 13,642 |
| CFO LTM | 16,843 |
| CFO 3Y Avg | 16,176 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 4.5% |
| Rev Chg 3Y Avg | 2.0% |
| Rev Chg Q | 3.2% |
| QoQ Delta Rev Chg LTM | 0.8% |
| Op Mgn LTM | 24.3% |
| Op Mgn 3Y Avg | 21.5% |
| QoQ Delta Op Mgn LTM | 2.3% |
| CFO/Rev LTM | 26.4% |
| CFO/Rev 3Y Avg | 27.3% |
| FCF/Rev LTM | 20.3% |
| FCF/Rev 3Y Avg | 21.1% |
Segment Financials
Revenue by Segment| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Single Segment | 0 | ||||
| Identification and development of therapeutic drug candidates | 0 | 0 | |||
| Symbio Supplies | 0 | 0 | |||
| Symbio Upfront license fee recognition over time | 0 | 0 | |||
| HanX–rigosertib-Upfront license payment recognized at a point in time | 2 | ||||
| Knight-Upfront license payment recognized at a point it time | 0 | ||||
| STA-Upfront license payment recognized at a point it time | 0 | ||||
| Total | 0 | 0 | 0 | 0 | 2 |
| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Single Segment | -19 | ||||
| Total | -19 |
Price Behavior
Price Behavior
| Market Price | $1.24 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 07/25/2013 | |
| Distance from 52W High | -90.8% | |
| 50 Days | 200 Days | |
| DMA Price | $2.25 | $1.90 |
| DMA Trend | down | indeterminate |
| Distance from DMA | -44.9% | -34.7% |
| 3M | 1YR | |
| Volatility | 145.8% | 121.0% |
| Downside Capture | 225.73 | 259.97 |
| Upside Capture | -8.98 | 0.51 |
| Correlation (SPY) | 24.7% | 20.3% |
TRAW Betas & Captures as of 11/30/2025
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 3.83 | 2.27 | 2.10 | 2.43 | 1.29 | 1.03 |
| Up Beta | 3.05 | 0.91 | 0.99 | 1.57 | 0.31 | 0.40 |
| Down Beta | 19.91 | 9.66 | 7.98 | 5.18 | 2.15 | 1.60 |
| Up Capture | 221% | 160% | 217% | 297% | 111% | 23% |
| Bmk +ve Days | 13 | 26 | 39 | 74 | 142 | 427 |
| Stock +ve Days | 8 | 17 | 28 | 54 | 105 | 321 |
| Down Capture | 189% | -121% | -184% | 106% | 137% | 108% |
| Bmk -ve Days | 7 | 16 | 24 | 52 | 107 | 323 |
| Stock -ve Days | 12 | 25 | 35 | 64 | 133 | 406 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Comparison of TRAW With Other Asset Classes (Last 1Y) | |||||||
|---|---|---|---|---|---|---|---|
| TRAW | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | -76.8% | 16.4% | 19.2% | 71.9% | 8.9% | 6.0% | -10.4% |
| Annualized Volatility | 193.3% | 17.3% | 19.5% | 19.3% | 15.3% | 17.1% | 35.0% |
| Sharpe Ratio | -0.07 | 0.72 | 0.78 | 2.69 | 0.36 | 0.18 | -0.12 |
| Correlation With Other Assets | 14.8% | 14.7% | -4.6% | 2.4% | 5.1% | 3.9% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Comparison of TRAW With Other Asset Classes (Last 5Y) | |||||||
|---|---|---|---|---|---|---|---|
| TRAW | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | -61.2% | 8.6% | 14.9% | 18.7% | 11.7% | 4.8% | 32.6% |
| Annualized Volatility | 126.9% | 14.5% | 17.1% | 15.5% | 18.7% | 18.9% | 48.7% |
| Sharpe Ratio | -0.25 | 0.41 | 0.70 | 0.97 | 0.51 | 0.17 | 0.59 |
| Correlation With Other Assets | 12.4% | 13.6% | 1.0% | 4.9% | 8.1% | 10.7% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Comparison of TRAW With Other Asset Classes (Last 10Y) | |||||||
|---|---|---|---|---|---|---|---|
| TRAW | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | -66.0% | 9.8% | 14.7% | 14.9% | 6.9% | 5.2% | 69.2% |
| Annualized Volatility | 120.7% | 16.6% | 18.0% | 14.8% | 17.6% | 20.8% | 55.8% |
| Sharpe Ratio | -0.36 | 0.48 | 0.70 | 0.83 | 0.31 | 0.22 | 0.90 |
| Correlation With Other Assets | 10.6% | 11.6% | 2.0% | 5.5% | 5.7% | 8.1% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/13/2025 | -17.3% | -1.4% | 4.7% |
| 8/14/2025 | -1.2% | -18.9% | 16.5% |
| 3/31/2025 | -4.2% | -18.3% | -40.4% |
| 11/14/2024 | -10.6% | -19.2% | -15.8% |
| 8/15/2024 | 4.9% | 6.7% | 1.9% |
| 11/14/2023 | -4.4% | -3.0% | 13.6% |
| 8/10/2023 | -5.9% | -22.0% | -23.5% |
| 3/16/2023 | 1.9% | -7.9% | -12.7% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 3 | 3 | 5 |
| # Negative | 14 | 14 | 12 |
| Median Positive | 1.9% | 2.3% | 12.7% |
| Median Negative | -4.5% | -9.2% | -18.4% |
| Max Positive | 4.9% | 6.7% | 16.5% |
| Max Negative | -17.3% | -22.0% | -77.8% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 9302025 | 11132025 | 10-Q 9/30/2025 |
| 6302025 | 8142025 | 10-Q 6/30/2025 |
| 3312025 | 5152025 | 10-Q 3/31/2025 |
| 12312024 | 3312025 | 10-K 12/31/2024 |
| 9302024 | 11142024 | 10-Q 9/30/2024 |
| 6302024 | 8152024 | 10-Q 6/30/2024 |
| 3312024 | 5152024 | 10-Q 3/31/2024 |
| 12312023 | 4012024 | 10-K 12/31/2023 |
| 9302023 | 11142023 | 10-Q 9/30/2023 |
| 6302023 | 8142023 | 10-Q 6/30/2023 |
| 3312023 | 5152023 | 10-Q 3/31/2023 |
| 12312022 | 3302023 | 10-K 12/31/2022 |
| 9302022 | 11142022 | 10-Q 9/30/2022 |
| 6302022 | 8152022 | 10-Q 6/30/2022 |
| 3312022 | 5132022 | 10-Q 3/31/2022 |
| 12312021 | 3212022 | 10-K 12/31/2021 |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.